Revance Therapeutics, Inc.

NASDAQ:RVNC

3.06 (USD) • At close December 27, 2024
Bedrijfsnaam Revance Therapeutics, Inc.
Symbool RVNC
Munteenheid USD
Prijs 3.06
Beurswaarde 319,433,400
Dividendpercentage 0%
52-weken bereik 2.3 - 9.745
Industrie Biotechnology
Sector Healthcare
CEO Mr. Mark J. Foley
Website https://www.revance.com

An error occurred while fetching data.

Over Revance Therapeutics, Inc.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines

Vergelijkbare Aandelen

Varex Imaging Corporation logo

Varex Imaging Corporation

VREX

14.82 USD

Sharecare, Inc. logo

Sharecare, Inc.

SHCR

1.43 USD

Ventyx Biosciences, Inc. logo

Ventyx Biosciences, Inc.

VTYX

2.38 USD

OrthoPediatrics Corp. logo

OrthoPediatrics Corp.

KIDS

22.89 USD

SNDL Inc. logo

SNDL Inc.

SNDL

1.79 USD

Procaps Group S.A. logo

Procaps Group S.A.

PROC

2.35 USD

Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

RXRX

7.39 USD

Simulations Plus, Inc. logo

Simulations Plus, Inc.

SLP

28.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)